Hmdb loader
Survey
Record Information
Version5.0
StatusExpected but not Quantified
Creation Date2012-09-06 15:16:49 UTC
Update Date2022-03-07 02:51:40 UTC
HMDB IDHMDB0014574
Secondary Accession Numbers
  • HMDB14574
Metabolite Identification
Common NameCefpiramide
DescriptionCefpiramide, also known as CPM or SM-1652, belongs to the class of organic compounds known as peptides. Peptides are compounds containing an amide derived from two or more amino carboxylic acid molecules (the same or different) by formation of a covalent bond from the carbonyl carbon of one to the nitrogen atom of another. Cefpiramide is a drug which is used for treatment of severe infections caused by susceptible bacteria such as p. aeruginosa. Based on a literature review a significant number of articles have been published on Cefpiramide.
Structure
Data?1582753195
Synonyms
ValueSource
CefpiramidoChEBI
CefpiramidumChEBI
CPMKegg
SM-1652HMDB
Cefpiramide sodiumHMDB
SumcefalHMDB
Cefpiramide, sodium saltHMDB
Chemical FormulaC25H24N8O7S2
Average Molecular Weight612.637
Monoisotopic Molecular Weight612.120936542
IUPAC Name(6R,7R)-7-[(2R)-2-[(4-hydroxy-6-methylpyridin-3-yl)formamido]-2-(4-hydroxyphenyl)acetamido]-3-{[(1-methyl-1H-1,2,3,4-tetrazol-5-yl)sulfanyl]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
Traditional Namecefpiramido
CAS Registry Number70797-11-4
SMILES
[H][C@]12SCC(CSC3=NN=NN3C)=C(N1C(=O)[C@@]2([H])NC(=O)[C@H](NC(=O)C1=C(O)C=C(C)N=C1)C1=CC=C(O)C=C1)C(O)=O
InChI Identifier
InChI=1S/C25H24N8O7S2/c1-11-7-16(35)15(8-26-11)20(36)27-17(12-3-5-14(34)6-4-12)21(37)28-18-22(38)33-19(24(39)40)13(9-41-23(18)33)10-42-25-29-30-31-32(25)2/h3-8,17-18,23,34H,9-10H2,1-2H3,(H,26,35)(H,27,36)(H,28,37)(H,39,40)/t17-,18-,23-/m1/s1
InChI KeyPWAUCHMQEXVFJR-PMAPCBKXSA-N
Chemical Taxonomy
Description Belongs to the class of organic compounds known as peptides. Peptides are compounds containing an amide derived from two or more amino carboxylic acid molecules (the same or different) by formation of a covalent bond from the carbonyl carbon of one to the nitrogen atom of another.
KingdomOrganic compounds
Super ClassOrganic acids and derivatives
ClassCarboxylic acids and derivatives
Sub ClassAmino acids, peptides, and analogues
Direct ParentPeptides
Alternative Parents
Substituents
  • Alpha peptide
  • Cephalosporin
  • N-acyl-alpha amino acid or derivatives
  • Alpha-amino acid amide
  • N-substituted-alpha-amino acid
  • Alpha-amino acid or derivatives
  • Phenylacetamide
  • Cephem
  • Nicotinamide
  • Pyridine carboxylic acid or derivatives
  • Aryl thioether
  • Dihydropyridine
  • Alkylarylthioether
  • Methylpyridine
  • Phenol
  • 1-hydroxy-2-unsubstituted benzenoid
  • Hydropyridine
  • Benzenoid
  • Meta-thiazine
  • Monocyclic benzene moiety
  • Pyridine
  • Heteroaromatic compound
  • Vinylogous amide
  • Beta-lactam
  • Azole
  • Tetrazole
  • Tertiary carboxylic acid amide
  • Azetidine
  • Cyclic ketone
  • Carboxamide group
  • Secondary carboxylic acid amide
  • Lactam
  • Organoheterocyclic compound
  • Azacycle
  • Dialkylthioether
  • Sulfenyl compound
  • Hemithioaminal
  • Thioether
  • Carboxylic acid
  • Monocarboxylic acid or derivatives
  • Carbonyl group
  • Organic oxide
  • Organosulfur compound
  • Organic oxygen compound
  • Organooxygen compound
  • Organonitrogen compound
  • Organic nitrogen compound
  • Organopnictogen compound
  • Hydrocarbon derivative
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors
Ontology
Physiological effectNot Available
Disposition
ProcessNot Available
RoleNot Available
Physical Properties
StateSolid
Experimental Molecular Properties
PropertyValueReference
Melting PointNot AvailableNot Available
Boiling PointNot AvailableNot Available
Water Solubility0.067 g/LNot Available
LogP-0.9Not Available
Experimental Chromatographic PropertiesNot Available
Predicted Molecular Properties
PropertyValueSource
Water Solubility0.067 g/LALOGPS
logP0.53ALOGPS
logP0.22ChemAxon
logS-4ALOGPS
pKa (Strongest Acidic)3.47ChemAxon
pKa (Strongest Basic)2.66ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count11ChemAxon
Hydrogen Donor Count5ChemAxon
Polar Surface Area212.76 ŲChemAxon
Rotatable Bond Count9ChemAxon
Refractivity164.81 m³·mol⁻¹ChemAxon
Polarizability58.79 ųChemAxon
Number of Rings5ChemAxon
BioavailabilityNoChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted Chromatographic Properties

Predicted Collision Cross Sections

PredictorAdduct TypeCCS Value (Å2)Reference
DarkChem[M+H]+232.99431661259
DarkChem[M-H]-223.25331661259
DeepCCS[M-2H]-258.8730932474
DeepCCS[M+Na]+232.83630932474
AllCCS[M+H]+231.832859911
AllCCS[M+H-H2O]+230.832859911
AllCCS[M+NH4]+232.632859911
AllCCS[M+Na]+232.932859911
AllCCS[M-H]-213.732859911
AllCCS[M+Na-2H]-215.332859911
AllCCS[M+HCOO]-217.232859911

Predicted Kovats Retention Indices

Underivatized

MetaboliteSMILESKovats RI ValueColumn TypeReference
Cefpiramide[H][C@]12SCC(CSC3=NN=NN3C)=C(N1C(=O)[C@@]2([H])NC(=O)[C@H](NC(=O)C1=C(O)C=C(C)N=C1)C1=CC=C(O)C=C1)C(O)=O6238.1Standard polar33892256
Cefpiramide[H][C@]12SCC(CSC3=NN=NN3C)=C(N1C(=O)[C@@]2([H])NC(=O)[C@H](NC(=O)C1=C(O)C=C(C)N=C1)C1=CC=C(O)C=C1)C(O)=O3686.8Standard non polar33892256
Cefpiramide[H][C@]12SCC(CSC3=NN=NN3C)=C(N1C(=O)[C@@]2([H])NC(=O)[C@H](NC(=O)C1=C(O)C=C(C)N=C1)C1=CC=C(O)C=C1)C(O)=O5456.7Semi standard non polar33892256

Derivatized

Derivative Name / StructureSMILESKovats RI ValueColumn TypeReference
Cefpiramide,1TMS,isomer #1CC1=CC(O[Si](C)(C)C)=C(C(=O)N[C@@H](C(=O)N[C@@H]2C(=O)N3C(C(=O)O)=C(CSC4=NN=NN4C)CS[C@H]23)C2=CC=C(O)C=C2)C=N15456.4Semi standard non polar33892256
Cefpiramide,1TMS,isomer #2CC1=CC(O)=C(C(=O)N[C@@H](C(=O)N[C@@H]2C(=O)N3C(C(=O)O)=C(CSC4=NN=NN4C)CS[C@H]23)C2=CC=C(O[Si](C)(C)C)C=C2)C=N15530.7Semi standard non polar33892256
Cefpiramide,1TMS,isomer #3CC1=CC(O)=C(C(=O)N[C@@H](C(=O)N[C@@H]2C(=O)N3C(C(=O)O[Si](C)(C)C)=C(CSC4=NN=NN4C)CS[C@H]23)C2=CC=C(O)C=C2)C=N15434.1Semi standard non polar33892256
Cefpiramide,1TMS,isomer #4CC1=CC(O)=C(C(=O)N[C@@H](C(=O)N([C@@H]2C(=O)N3C(C(=O)O)=C(CSC4=NN=NN4C)CS[C@H]23)[Si](C)(C)C)C2=CC=C(O)C=C2)C=N15328.4Semi standard non polar33892256
Cefpiramide,1TMS,isomer #5CC1=CC(O)=C(C(=O)N([C@@H](C(=O)N[C@@H]2C(=O)N3C(C(=O)O)=C(CSC4=NN=NN4C)CS[C@H]23)C2=CC=C(O)C=C2)[Si](C)(C)C)C=N15314.0Semi standard non polar33892256
Cefpiramide,2TMS,isomer #1CC1=CC(O[Si](C)(C)C)=C(C(=O)N[C@@H](C(=O)N[C@@H]2C(=O)N3C(C(=O)O[Si](C)(C)C)=C(CSC4=NN=NN4C)CS[C@H]23)C2=CC=C(O)C=C2)C=N15309.2Semi standard non polar33892256
Cefpiramide,2TMS,isomer #10CC1=CC(O)=C(C(=O)N([C@@H](C(=O)N([C@@H]2C(=O)N3C(C(=O)O)=C(CSC4=NN=NN4C)CS[C@H]23)[Si](C)(C)C)C2=CC=C(O)C=C2)[Si](C)(C)C)C=N15073.2Semi standard non polar33892256
Cefpiramide,2TMS,isomer #2CC1=CC(O[Si](C)(C)C)=C(C(=O)N[C@@H](C(=O)N[C@@H]2C(=O)N3C(C(=O)O)=C(CSC4=NN=NN4C)CS[C@H]23)C2=CC=C(O[Si](C)(C)C)C=C2)C=N15382.9Semi standard non polar33892256
Cefpiramide,2TMS,isomer #3CC1=CC(O[Si](C)(C)C)=C(C(=O)N([C@@H](C(=O)N[C@@H]2C(=O)N3C(C(=O)O)=C(CSC4=NN=NN4C)CS[C@H]23)C2=CC=C(O)C=C2)[Si](C)(C)C)C=N15179.9Semi standard non polar33892256
Cefpiramide,2TMS,isomer #4CC1=CC(O[Si](C)(C)C)=C(C(=O)N[C@@H](C(=O)N([C@@H]2C(=O)N3C(C(=O)O)=C(CSC4=NN=NN4C)CS[C@H]23)[Si](C)(C)C)C2=CC=C(O)C=C2)C=N15194.8Semi standard non polar33892256
Cefpiramide,2TMS,isomer #5CC1=CC(O)=C(C(=O)N[C@@H](C(=O)N[C@@H]2C(=O)N3C(C(=O)O[Si](C)(C)C)=C(CSC4=NN=NN4C)CS[C@H]23)C2=CC=C(O[Si](C)(C)C)C=C2)C=N15395.0Semi standard non polar33892256
Cefpiramide,2TMS,isomer #6CC1=CC(O)=C(C(=O)N([C@@H](C(=O)N[C@@H]2C(=O)N3C(C(=O)O)=C(CSC4=NN=NN4C)CS[C@H]23)C2=CC=C(O[Si](C)(C)C)C=C2)[Si](C)(C)C)C=N15225.6Semi standard non polar33892256
Cefpiramide,2TMS,isomer #7CC1=CC(O)=C(C(=O)N[C@@H](C(=O)N([C@@H]2C(=O)N3C(C(=O)O)=C(CSC4=NN=NN4C)CS[C@H]23)[Si](C)(C)C)C2=CC=C(O[Si](C)(C)C)C=C2)C=N15268.7Semi standard non polar33892256
Cefpiramide,2TMS,isomer #8CC1=CC(O)=C(C(=O)N([C@@H](C(=O)N[C@@H]2C(=O)N3C(C(=O)O[Si](C)(C)C)=C(CSC4=NN=NN4C)CS[C@H]23)C2=CC=C(O)C=C2)[Si](C)(C)C)C=N15155.1Semi standard non polar33892256
Cefpiramide,2TMS,isomer #9CC1=CC(O)=C(C(=O)N[C@@H](C(=O)N([C@@H]2C(=O)N3C(C(=O)O[Si](C)(C)C)=C(CSC4=NN=NN4C)CS[C@H]23)[Si](C)(C)C)C2=CC=C(O)C=C2)C=N15157.5Semi standard non polar33892256
Cefpiramide,3TMS,isomer #1CC1=CC(O[Si](C)(C)C)=C(C(=O)N[C@@H](C(=O)N[C@@H]2C(=O)N3C(C(=O)O[Si](C)(C)C)=C(CSC4=NN=NN4C)CS[C@H]23)C2=CC=C(O[Si](C)(C)C)C=C2)C=N15328.2Semi standard non polar33892256
Cefpiramide,3TMS,isomer #10CC1=CC(O)=C(C(=O)N([C@@H](C(=O)N([C@@H]2C(=O)N3C(C(=O)O[Si](C)(C)C)=C(CSC4=NN=NN4C)CS[C@H]23)[Si](C)(C)C)C2=CC=C(O)C=C2)[Si](C)(C)C)C=N14951.1Semi standard non polar33892256
Cefpiramide,3TMS,isomer #2CC1=CC(O[Si](C)(C)C)=C(C(=O)N([C@@H](C(=O)N[C@@H]2C(=O)N3C(C(=O)O[Si](C)(C)C)=C(CSC4=NN=NN4C)CS[C@H]23)C2=CC=C(O)C=C2)[Si](C)(C)C)C=N15085.0Semi standard non polar33892256
Cefpiramide,3TMS,isomer #3CC1=CC(O[Si](C)(C)C)=C(C(=O)N[C@@H](C(=O)N([C@@H]2C(=O)N3C(C(=O)O[Si](C)(C)C)=C(CSC4=NN=NN4C)CS[C@H]23)[Si](C)(C)C)C2=CC=C(O)C=C2)C=N15083.1Semi standard non polar33892256
Cefpiramide,3TMS,isomer #4CC1=CC(O[Si](C)(C)C)=C(C(=O)N([C@@H](C(=O)N[C@@H]2C(=O)N3C(C(=O)O)=C(CSC4=NN=NN4C)CS[C@H]23)C2=CC=C(O[Si](C)(C)C)C=C2)[Si](C)(C)C)C=N15147.0Semi standard non polar33892256
Cefpiramide,3TMS,isomer #5CC1=CC(O[Si](C)(C)C)=C(C(=O)N[C@@H](C(=O)N([C@@H]2C(=O)N3C(C(=O)O)=C(CSC4=NN=NN4C)CS[C@H]23)[Si](C)(C)C)C2=CC=C(O[Si](C)(C)C)C=C2)C=N15180.7Semi standard non polar33892256
Cefpiramide,3TMS,isomer #6CC1=CC(O[Si](C)(C)C)=C(C(=O)N([C@@H](C(=O)N([C@@H]2C(=O)N3C(C(=O)O)=C(CSC4=NN=NN4C)CS[C@H]23)[Si](C)(C)C)C2=CC=C(O)C=C2)[Si](C)(C)C)C=N14994.0Semi standard non polar33892256
Cefpiramide,3TMS,isomer #7CC1=CC(O)=C(C(=O)N([C@@H](C(=O)N[C@@H]2C(=O)N3C(C(=O)O[Si](C)(C)C)=C(CSC4=NN=NN4C)CS[C@H]23)C2=CC=C(O[Si](C)(C)C)C=C2)[Si](C)(C)C)C=N15134.6Semi standard non polar33892256
Cefpiramide,3TMS,isomer #8CC1=CC(O)=C(C(=O)N[C@@H](C(=O)N([C@@H]2C(=O)N3C(C(=O)O[Si](C)(C)C)=C(CSC4=NN=NN4C)CS[C@H]23)[Si](C)(C)C)C2=CC=C(O[Si](C)(C)C)C=C2)C=N15153.7Semi standard non polar33892256
Cefpiramide,3TMS,isomer #9CC1=CC(O)=C(C(=O)N([C@@H](C(=O)N([C@@H]2C(=O)N3C(C(=O)O)=C(CSC4=NN=NN4C)CS[C@H]23)[Si](C)(C)C)C2=CC=C(O[Si](C)(C)C)C=C2)[Si](C)(C)C)C=N15039.8Semi standard non polar33892256
Cefpiramide,1TBDMS,isomer #1CC1=CC(O[Si](C)(C)C(C)(C)C)=C(C(=O)N[C@@H](C(=O)N[C@@H]2C(=O)N3C(C(=O)O)=C(CSC4=NN=NN4C)CS[C@H]23)C2=CC=C(O)C=C2)C=N15648.3Semi standard non polar33892256
Cefpiramide,1TBDMS,isomer #2CC1=CC(O)=C(C(=O)N[C@@H](C(=O)N[C@@H]2C(=O)N3C(C(=O)O)=C(CSC4=NN=NN4C)CS[C@H]23)C2=CC=C(O[Si](C)(C)C(C)(C)C)C=C2)C=N15735.4Semi standard non polar33892256
Cefpiramide,1TBDMS,isomer #3CC1=CC(O)=C(C(=O)N[C@@H](C(=O)N[C@@H]2C(=O)N3C(C(=O)O[Si](C)(C)C(C)(C)C)=C(CSC4=NN=NN4C)CS[C@H]23)C2=CC=C(O)C=C2)C=N15690.1Semi standard non polar33892256
Cefpiramide,1TBDMS,isomer #4CC1=CC(O)=C(C(=O)N[C@@H](C(=O)N([C@@H]2C(=O)N3C(C(=O)O)=C(CSC4=NN=NN4C)CS[C@H]23)[Si](C)(C)C(C)(C)C)C2=CC=C(O)C=C2)C=N15622.6Semi standard non polar33892256
Cefpiramide,1TBDMS,isomer #5CC1=CC(O)=C(C(=O)N([C@@H](C(=O)N[C@@H]2C(=O)N3C(C(=O)O)=C(CSC4=NN=NN4C)CS[C@H]23)C2=CC=C(O)C=C2)[Si](C)(C)C(C)(C)C)C=N15627.0Semi standard non polar33892256
Cefpiramide,2TBDMS,isomer #1CC1=CC(O[Si](C)(C)C(C)(C)C)=C(C(=O)N[C@@H](C(=O)N[C@@H]2C(=O)N3C(C(=O)O[Si](C)(C)C(C)(C)C)=C(CSC4=NN=NN4C)CS[C@H]23)C2=CC=C(O)C=C2)C=N15741.9Semi standard non polar33892256
Cefpiramide,2TBDMS,isomer #10CC1=CC(O)=C(C(=O)N([C@@H](C(=O)N([C@@H]2C(=O)N3C(C(=O)O)=C(CSC4=NN=NN4C)CS[C@H]23)[Si](C)(C)C(C)(C)C)C2=CC=C(O)C=C2)[Si](C)(C)C(C)(C)C)C=N15548.3Semi standard non polar33892256
Cefpiramide,2TBDMS,isomer #2CC1=CC(O[Si](C)(C)C(C)(C)C)=C(C(=O)N[C@@H](C(=O)N[C@@H]2C(=O)N3C(C(=O)O)=C(CSC4=NN=NN4C)CS[C@H]23)C2=CC=C(O[Si](C)(C)C(C)(C)C)C=C2)C=N15794.4Semi standard non polar33892256
Cefpiramide,2TBDMS,isomer #3CC1=CC(O[Si](C)(C)C(C)(C)C)=C(C(=O)N([C@@H](C(=O)N[C@@H]2C(=O)N3C(C(=O)O)=C(CSC4=NN=NN4C)CS[C@H]23)C2=CC=C(O)C=C2)[Si](C)(C)C(C)(C)C)C=N15642.2Semi standard non polar33892256
Cefpiramide,2TBDMS,isomer #4CC1=CC(O[Si](C)(C)C(C)(C)C)=C(C(=O)N[C@@H](C(=O)N([C@@H]2C(=O)N3C(C(=O)O)=C(CSC4=NN=NN4C)CS[C@H]23)[Si](C)(C)C(C)(C)C)C2=CC=C(O)C=C2)C=N15626.7Semi standard non polar33892256
Cefpiramide,2TBDMS,isomer #5CC1=CC(O)=C(C(=O)N[C@@H](C(=O)N[C@@H]2C(=O)N3C(C(=O)O[Si](C)(C)C(C)(C)C)=C(CSC4=NN=NN4C)CS[C@H]23)C2=CC=C(O[Si](C)(C)C(C)(C)C)C=C2)C=N15829.8Semi standard non polar33892256
Cefpiramide,2TBDMS,isomer #6CC1=CC(O)=C(C(=O)N([C@@H](C(=O)N[C@@H]2C(=O)N3C(C(=O)O)=C(CSC4=NN=NN4C)CS[C@H]23)C2=CC=C(O[Si](C)(C)C(C)(C)C)C=C2)[Si](C)(C)C(C)(C)C)C=N15706.8Semi standard non polar33892256
Cefpiramide,2TBDMS,isomer #7CC1=CC(O)=C(C(=O)N[C@@H](C(=O)N([C@@H]2C(=O)N3C(C(=O)O)=C(CSC4=NN=NN4C)CS[C@H]23)[Si](C)(C)C(C)(C)C)C2=CC=C(O[Si](C)(C)C(C)(C)C)C=C2)C=N15717.7Semi standard non polar33892256
Cefpiramide,2TBDMS,isomer #8CC1=CC(O)=C(C(=O)N([C@@H](C(=O)N[C@@H]2C(=O)N3C(C(=O)O[Si](C)(C)C(C)(C)C)=C(CSC4=NN=NN4C)CS[C@H]23)C2=CC=C(O)C=C2)[Si](C)(C)C(C)(C)C)C=N15661.1Semi standard non polar33892256
Cefpiramide,2TBDMS,isomer #9CC1=CC(O)=C(C(=O)N[C@@H](C(=O)N([C@@H]2C(=O)N3C(C(=O)O[Si](C)(C)C(C)(C)C)=C(CSC4=NN=NN4C)CS[C@H]23)[Si](C)(C)C(C)(C)C)C2=CC=C(O)C=C2)C=N15630.4Semi standard non polar33892256
Spectra

GC-MS Spectra

Spectrum TypeDescriptionSplash KeyDeposition DateSourceView
Predicted GC-MSPredicted GC-MS Spectrum - Cefpiramide GC-MS (Non-derivatized) - 70eV, Positivesplash10-0a4i-0190100000-3a610343fcd1d398dda62017-09-01Wishart LabView Spectrum
Predicted GC-MSPredicted GC-MS Spectrum - Cefpiramide GC-MS (1 TMS) - 70eV, Positivesplash10-0ap0-6690032000-262799ec7d036af946892017-10-06Wishart LabView Spectrum
Predicted GC-MSPredicted GC-MS Spectrum - Cefpiramide GC-MS (TMS_1_2) - 70eV, PositiveNot Available2021-10-16Wishart LabView Spectrum
Predicted GC-MSPredicted GC-MS Spectrum - Cefpiramide GC-MS (TMS_1_3) - 70eV, PositiveNot Available2021-10-16Wishart LabView Spectrum
Predicted GC-MSPredicted GC-MS Spectrum - Cefpiramide GC-MS (TMS_1_4) - 70eV, PositiveNot Available2021-10-16Wishart LabView Spectrum
Predicted GC-MSPredicted GC-MS Spectrum - Cefpiramide GC-MS (TMS_1_5) - 70eV, PositiveNot Available2021-10-16Wishart LabView Spectrum
Predicted GC-MSPredicted GC-MS Spectrum - Cefpiramide GC-MS (TMS_2_1) - 70eV, PositiveNot Available2021-10-16Wishart LabView Spectrum
Predicted GC-MSPredicted GC-MS Spectrum - Cefpiramide GC-MS (TMS_2_2) - 70eV, PositiveNot Available2021-10-16Wishart LabView Spectrum
Predicted GC-MSPredicted GC-MS Spectrum - Cefpiramide GC-MS (TMS_2_3) - 70eV, PositiveNot Available2021-10-16Wishart LabView Spectrum
Predicted GC-MSPredicted GC-MS Spectrum - Cefpiramide GC-MS (TMS_2_4) - 70eV, PositiveNot Available2021-10-16Wishart LabView Spectrum
Predicted GC-MSPredicted GC-MS Spectrum - Cefpiramide GC-MS (TMS_2_5) - 70eV, PositiveNot Available2021-10-16Wishart LabView Spectrum
Predicted GC-MSPredicted GC-MS Spectrum - Cefpiramide GC-MS (TMS_2_6) - 70eV, PositiveNot Available2021-10-16Wishart LabView Spectrum
Predicted GC-MSPredicted GC-MS Spectrum - Cefpiramide GC-MS (TMS_2_7) - 70eV, PositiveNot Available2021-10-16Wishart LabView Spectrum
Predicted GC-MSPredicted GC-MS Spectrum - Cefpiramide GC-MS (TMS_2_8) - 70eV, PositiveNot Available2021-10-16Wishart LabView Spectrum
Predicted GC-MSPredicted GC-MS Spectrum - Cefpiramide GC-MS (TMS_2_9) - 70eV, PositiveNot Available2021-10-16Wishart LabView Spectrum
Predicted GC-MSPredicted GC-MS Spectrum - Cefpiramide GC-MS (TMS_2_10) - 70eV, PositiveNot Available2021-10-16Wishart LabView Spectrum
Predicted GC-MSPredicted GC-MS Spectrum - Cefpiramide GC-MS (TMS_3_1) - 70eV, PositiveNot Available2021-10-16Wishart LabView Spectrum
Predicted GC-MSPredicted GC-MS Spectrum - Cefpiramide GC-MS (TMS_3_2) - 70eV, PositiveNot Available2021-10-16Wishart LabView Spectrum
Predicted GC-MSPredicted GC-MS Spectrum - Cefpiramide GC-MS (TMS_3_3) - 70eV, PositiveNot Available2021-10-16Wishart LabView Spectrum
Predicted GC-MSPredicted GC-MS Spectrum - Cefpiramide GC-MS (TMS_3_4) - 70eV, PositiveNot Available2021-10-16Wishart LabView Spectrum
Predicted GC-MSPredicted GC-MS Spectrum - Cefpiramide GC-MS (TMS_3_5) - 70eV, PositiveNot Available2021-10-16Wishart LabView Spectrum
Predicted GC-MSPredicted GC-MS Spectrum - Cefpiramide GC-MS (TMS_3_6) - 70eV, PositiveNot Available2021-10-16Wishart LabView Spectrum
Predicted GC-MSPredicted GC-MS Spectrum - Cefpiramide GC-MS (TMS_3_7) - 70eV, PositiveNot Available2021-10-16Wishart LabView Spectrum
Predicted GC-MSPredicted GC-MS Spectrum - Cefpiramide GC-MS (TMS_3_8) - 70eV, PositiveNot Available2021-10-16Wishart LabView Spectrum
Predicted GC-MSPredicted GC-MS Spectrum - Cefpiramide GC-MS (TMS_3_9) - 70eV, PositiveNot Available2021-10-16Wishart LabView Spectrum

MS/MS Spectra

Spectrum TypeDescriptionSplash KeyDeposition DateSourceView
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Cefpiramide 10V, Positive-QTOFsplash10-05i3-1095151000-92abd90f62711e4b473c2016-06-03Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Cefpiramide 20V, Positive-QTOFsplash10-0abi-2493100000-ef6a3fd20e699b3093ff2016-06-03Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Cefpiramide 40V, Positive-QTOFsplash10-0abi-1590000000-e6b1c4b8020103cdfb972016-06-03Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Cefpiramide 10V, Negative-QTOFsplash10-014l-1619041000-aa3e6e4912cbf04bb33d2016-08-03Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Cefpiramide 20V, Negative-QTOFsplash10-0aor-9612000000-50a4d1c82eae2b589f0a2016-08-03Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Cefpiramide 40V, Negative-QTOFsplash10-0aou-9821000000-cd698beec1f947a53c9c2016-08-03Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Cefpiramide 10V, Positive-QTOFsplash10-03di-0458904000-3032d4ddc3c8f7b51cff2021-09-22Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Cefpiramide 20V, Positive-QTOFsplash10-052r-1976121000-db6d805969c93a849ecb2021-09-22Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Cefpiramide 40V, Positive-QTOFsplash10-000i-1922120000-98285a42e6de6a4f713e2021-09-22Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Cefpiramide 10V, Negative-QTOFsplash10-004i-0001092000-141daf7cdb4006d571252021-09-23Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Cefpiramide 20V, Negative-QTOFsplash10-06e9-1960021000-bb13589005f1776e4ca82021-09-23Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Cefpiramide 40V, Negative-QTOFsplash10-05mo-9810020000-c7546729a2f25176b49a2021-09-23Wishart LabView Spectrum
Biological Properties
Cellular Locations
  • Cytoplasm
  • Extracellular
  • Membrane
Biospecimen Locations
  • Blood
  • Urine
Tissue LocationsNot Available
Pathways
Normal Concentrations
BiospecimenStatusValueAgeSexConditionReferenceDetails
BloodExpected but not QuantifiedNot QuantifiedNot AvailableNot AvailableTaking drug identified by DrugBank entry DB00430 details
UrineExpected but not QuantifiedNot QuantifiedNot AvailableNot AvailableTaking drug identified by DrugBank entry DB00430 details
Abnormal Concentrations
Not Available
Associated Disorders and Diseases
Disease ReferencesNone
Associated OMIM IDsNone
DrugBank IDDB00430
Phenol Explorer Compound IDNot Available
FooDB IDNot Available
KNApSAcK IDNot Available
Chemspider ID552192
KEGG Compound IDC13376
BioCyc IDNot Available
BiGG IDNot Available
Wikipedia LinkCefpiramide
METLIN IDNot Available
PubChem Compound636405
PDB IDNot Available
ChEBI ID59213
Food Biomarker OntologyNot Available
VMH IDNot Available
MarkerDB IDNot Available
Good Scents IDNot Available
References
Synthesis ReferenceNot Available
Material Safety Data Sheet (MSDS)Not Available
General References
  1. Sampi K, Hattori M: [Comparative study of cefpiramide + amikacin versus piperacillin + amikacin in granulocytopenic patients: a randomized, prospective study]. Gan To Kagaku Ryoho. 1992 Aug;19(9):1315-20. [PubMed:1503486 ]
  2. Iakovlev VP, Vishnevskii VA, Khlebnikov EP, Khadin IM, Plavlova MV, Elagina LV, Izotova GN: [Cefpiramide (Tamicin) in the treatment of purulent complications of abdominal surgery]. Antibiot Khimioter. 1995 Sep;40(9):30-4. [PubMed:8651827 ]
  3. Wang H, Yu Y, Xie X, Wang C, Zhang Y, Yuan Y, Zhang X, Liu J, Wang P, Chen M: In-vitro antibacterial activities of cefpiramide and other broad-spectrum antibiotics against 440 clinical isolates in China. J Infect Chemother. 2000 Jun;6(2):81-5. [PubMed:11810540 ]